Irvine, California, May 24, 2023

Urine-Based Bladder Cancer Test, EarlyTect BCD has been accepted for publication in the Journal of Molecular Diagnostics. The study, titled “Evaluation of Sensitive Urine DNA-based PENK Methylation Test for Detecting Bladder Cancer in Patients with Hematuria,” showcases the test’s effectiveness in identifying bladder cancer in patients experiencing hematuria. The non-invasive test demonstrated over 90% sensitivity in detecting early-stage bladder cancer, potentially revolutionizing diagnosis and improving patient outcomes. This significant milestone highlights the test’s effectiveness in detecting bladder cancer in patients with hematuria, offering a promising non-invasive approach for early diagnosis.

Further research and clinical validation studies are already underway to refine and expand the application of EarlyTect BCD, with the goal of making this cutting-edge technology widely accessible to medical professionals and patients. The potential to detect bladder cancer at an early stage through a simple urine test brings hope for improved prognosis and treatment outcomes for countless individuals worldwide.

EarlyTect BCD received FDA Breakthrough Designation in April this year, acknowledging its revolutionary potential to transform bladder cancer diagnosis.